



Press Release

BioApex, s.r.o. Grant Update

Olomouc, Czech Republic (November 1, 2016) – BioApex, s.r.o., a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted compounds to treat a diverse range of serious cell-cycle related skin disorders, today announced an update to its recent activities under the Grant from the Regional Authority of the Olomouc Region to encourage the collaboration between research organizations and companies from the Olomouc region, specifically the development of new and affordable technologies for the preparation of certain purine derivatives.

Since May 2015, when the Grant was awarded, BioApex, in close cooperation with the Palacký University, developed a new generation of proprietary purine derivatives with anticancer activities. Based on initial findings (what are they, Mirek?), the new purine derivatives are believed to potentially be effective in the treatment of melanomas. BioApex is now working on technologies for the pilot-scale preparation of the key substance, methods of characterization of pilot batches and test pilot batches in terms of cellular and molecular-biological activity, all required for the design of the preclinical and clinical pathway.

About BioApex, s.r.o: BioApex is active in the very broad fields of cell division related disorders. BioApex is focused on the research and development of its portfolio of proprietary, small molecule-like compounds. BioApex owns a proprietary portfolio of small molecule-like compounds that have a wide range of biological activities, including antioxidant, anti-inflammatory, anti-senescent, pro-differentiation as well as other activities which are especially useful in pharmaceutical and cosmetic applications.

Proprietary compound compositions possess growth-regulatory, differentiating, anti-senescent and anti-aging properties with improved selectivity and efficiencies and lower toxicities than analogues known heretofore. There is longstanding research describing the potential benefits of the biological activities of such compounds in tissue-repair, cancer and multiples sclerosis treatment, to name just a few areas. They are also very potent inhibitors of carbonyl reductase (NADPH).

The compounds are naturally occurring, nontoxic and nonmutagenic. BioApex believes that, to date, there are no commercially available compounds that combine the same mode of action and effectiveness with minimal side effects.

BioApex plans to advance a group of promising compounds to clinical testing for use in both cosmetic skin care and drug applications. For the commercialization of its compounds, BioApex plans to partner with companies that have specific industry expertise and established sales and marketing channels.

For more information, visit the company's website at www.bioapex.cz